Literature DB >> 11601968

Targeting RNA with small-molecule drugs: therapeutic promise and chemical challenges.

J Gallego1, G Varani.   

Abstract

Researchers' increasing awareness of the essential role played by RNA in many biological processes and in the progression of disease makes the discovery of new RNA targets an emerging field in drug discovery. Since most existing pharmacologically active compounds bind proteins, RNA provides nearly untapped opportunities for pharmacological development. The elucidation of the structure of the ribosome and other cellular and viral RNA motifs creates the opportunity for discovering new drug-like compounds that inhibit RNA function. However, further advances in understanding the chemistry and structure of RNA recognition are needed before these promises are fulfilled.

Mesh:

Substances:

Year:  2001        PMID: 11601968     DOI: 10.1021/ar000118k

Source DB:  PubMed          Journal:  Acc Chem Res        ISSN: 0001-4842            Impact factor:   22.384


  68 in total

1.  High throughput screening of library compounds against an oligonucleotide substructure of an RNA target.

Authors:  Karen B Gooding; Richard Higgs; Barry Hodge; Eric Stauffer; Beverly Heinz; Kevin McKnight; Krista Phipps; Michael Shapiro; Malcolm Winkler; Wai-Leung Ng; Randall K Julian
Journal:  J Am Soc Mass Spectrom       Date:  2004-06       Impact factor: 3.109

2.  Interactions of protein side chains with RNA defined with REDOR solid state NMR.

Authors:  Wei Huang; Gabriele Varani; Gary P Drobny
Journal:  J Biomol NMR       Date:  2011-09-25       Impact factor: 2.835

3.  Design of RNA-targeting macrocyclic peptides.

Authors:  Matthew J Walker; Gabriele Varani
Journal:  Methods Enzymol       Date:  2019-06-13       Impact factor: 1.600

4.  Fluorescent pyrimidine ribonucleotide: synthesis, enzymatic incorporation, and utilization.

Authors:  Seergazhi G Srivatsan; Yitzhak Tor
Journal:  J Am Chem Soc       Date:  2007-01-26       Impact factor: 15.419

5.  Structure and Dynamics of RNA Repeat Expansions That Cause Huntington's Disease and Myotonic Dystrophy Type 1.

Authors:  Jonathan L Chen; Damian M VanEtten; Matthew A Fountain; Ilyas Yildirim; Matthew D Disney
Journal:  Biochemistry       Date:  2017-06-29       Impact factor: 3.162

6.  Synthesis and stereospecificity of 4,5-disubstituted oxazolidinone ligands binding to T-box riboswitch RNA.

Authors:  Crina M Orac; Shu Zhou; John A Means; David Boehm; Stephen C Bergmeier; Jennifer V Hines
Journal:  J Med Chem       Date:  2011-08-31       Impact factor: 7.446

7.  Non-Natural Linker Configuration in 2,6-Dipeptidyl-Anthraquinones Enhances the Inhibition of TAR RNA Binding/Annealing Activities by HIV-1 NC and Tat Proteins.

Authors:  Alice Sosic; Irene Saccone; Caterina Carraro; Thomas Kenderdine; Elia Gamba; Giuseppe Caliendo; Angela Corvino; Paola Di Vaio; Ferdinando Fiorino; Elisa Magli; Elisa Perissutti; Vincenzo Santagada; Beatrice Severino; Valentina Spada; Dan Fabris; Francesco Frecentese; Barbara Gatto
Journal:  Bioconjug Chem       Date:  2018-06-12       Impact factor: 4.774

8.  Simultaneous recognition of HIV-1 TAR RNA bulge and loop sequences by cyclic peptide mimics of Tat protein.

Authors:  Amy Davidson; Thomas C Leeper; Zafiria Athanassiou; Krystyna Patora-Komisarska; Jonathan Karn; John A Robinson; Gabriele Varani
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-07       Impact factor: 11.205

9.  A mutate-and-map strategy accurately infers the base pairs of a 35-nucleotide model RNA.

Authors:  Wipapat Kladwang; Pablo Cordero; Rhiju Das
Journal:  RNA       Date:  2011-01-14       Impact factor: 4.942

10.  FRET enabled real time detection of RNA-small molecule binding.

Authors:  Yun Xie; Andrew V Dix; Yitzhak Tor
Journal:  J Am Chem Soc       Date:  2009-12-09       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.